BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28540987)

  • 21. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic instability, CpG island methylator phenotype, and proliferative activity are distinct differences between diminutive and small tubular adenoma of the colorectum.
    Nando Y; Watari J; Ito C; Hara K; Yamasaki T; Okugawa T; Kondo T; Kono T; Tozawa K; Tomita T; Ohda Y; Oshima T; Fukui H; Matsubara N; Tomita N; Hirota S; Miwa H
    Hum Pathol; 2017 Feb; 60():37-45. PubMed ID: 27746269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Changing Spectrum of Colorectal Cancer Biology With Age: Implications for the Young Patient.
    Chouhan H; Ferrandon S; DeVecchio J; Kalady MF; Church JM
    Dis Colon Rectum; 2019 Jan; 62(1):21-26. PubMed ID: 30394984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
    Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
    Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS, BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2, DAPK1, MGMT, HIC1 and p16 genes in colorectal cancer patients.
    Bagci B; Sari M; Karadayi K; Turan M; Ozdemir O; Bagci G
    Cancer Biomark; 2016 Jun; 17(2):133-43. PubMed ID: 27540971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.
    Sanchez JA; Krumroy L; Plummer S; Aung P; Merkulova A; Skacel M; DeJulius KL; Manilich E; Church JM; Casey G; Kalady MF
    Br J Surg; 2009 Oct; 96(10):1196-204. PubMed ID: 19787768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients.
    Naghibalhossaini F; Hosseini HM; Mokarram P; Zamani M
    Pathol Oncol Res; 2011 Dec; 17(4):819-25. PubMed ID: 21455633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
    Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
    Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
    Laskar RS; Ghosh SK; Talukdar FR
    Mol Carcinog; 2015 Dec; 54(12):1786-95. PubMed ID: 25418895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas.
    Fennell L; Dumenil T; Wockner L; Hartel G; Nones K; Bond C; Borowsky J; Liu C; McKeone D; Bowdler L; Montgomery G; Klein K; Hoffmann I; Patch AM; Kazakoff S; Pearson J; Waddell N; Wirapati P; Lochhead P; Imamura Y; Ogino S; Shao R; Tejpar S; Leggett B; Whitehall V
    Cell Mol Gastroenterol Hepatol; 2019; 8(2):269-290. PubMed ID: 30954552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.
    Vedeld HM; Merok M; Jeanmougin M; Danielsen SA; Honne H; Presthus GK; Svindland A; Sjo OH; Hektoen M; Eknaes M; Nesbakken A; Lothe RA; Lind GE
    Int J Cancer; 2017 Sep; 141(5):967-976. PubMed ID: 28542846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.
    Loh M; Liem N; Vaithilingam A; Lim PL; Sapari NS; Elahi E; Mok ZY; Cheng CL; Yan B; Pang B; Salto-Tellez M; Yong WP; Iacopetta B; Soong R
    BMC Gastroenterol; 2014 Mar; 14():55. PubMed ID: 24674026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
    Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
    Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
    Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions.
    Ito M; Mitsuhashi K; Igarashi H; Nosho K; Naito T; Yoshii S; Takahashi H; Fujita M; Sukawa Y; Yamamoto E; Takahashi T; Adachi Y; Nojima M; Sasaki Y; Tokino T; Baba Y; Maruyama R; Suzuki H; Imai K; Yamamoto H; Shinomura Y
    Int J Cancer; 2014 Dec; 135(11):2507-15. PubMed ID: 24752710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of laterally spreading type and JC virus with methylator phenotype status in colorectal adenoma.
    Nosho K; Yamamoto H; Takahashi T; Mikami M; Hizaki K; Maehata T; Taniguchi H; Yamaoka S; Adachi Y; Itoh F; Imai K; Shinomura Y
    Hum Pathol; 2008 May; 39(5):767-75. PubMed ID: 18284934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors.
    Poeta ML; Massi E; Parrella P; Pellegrini P; De Robertis M; Copetti M; Rabitti C; Perrone G; Muda AO; Molinari F; Zanellato E; Crippa S; Caputo D; Caricato M; Frattini M; Coppola R; Fazio VM
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1133-43. PubMed ID: 22927297
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation and identification of factors related to
    Lin L; Chen GY; Xu CW; Wang HY; Wu YF; Fang MY
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C191-C198. PubMed ID: 28230016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.